

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

INSIDE INFORMATION
ENTERING INTO LICENSE AND COLLABORATION
AGREEMENT WITH MODERNATX, INC.

This announcement is made by HBM Holdings Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to announce that Nona Biosciences (Suzhou) Co., Ltd (“**Nona Biosciences**”, formerly known as Harbour BioMed (Suzhou) Co. Ltd), a subsidiary wholly owned by the Company, and ModernaTX, Inc. (“**Moderna**”) have entered into a license and collaboration agreement (the “**Agreement**”). The strategic collaboration will focus on the discovery and development of nucleic acid based immunotherapies using the Company’s proprietary heavy chain only (“**HCAb**”) antibody discovery platform.

Upon the execution of the Agreement and subject to terms and conditions thereof, Moderna will be granted an exclusive sub-licensable license to exploit a panel of sequences against multiple targets, derived from the Company’s HCAb platform, to develop products using nucleic acids. Moderna will assume full responsibility for all upcoming development, manufacturing, regulatory, and commercialization activities under the Agreement.

Pursuant to the Agreement, Nona Biosciences shall receive US\$6 million in a one-time, non-refundable upfront payment and up to approximately US\$500 million in potential milestone payments based on pending achievement of certain regulatory, development, and sales milestones. Further, Nona Biosciences will be eligible to receive tiered royalties from Moderna for each product developed under the Agreement.

Moreover, pursuant to the Agreement, Moderna will be granted an option to obtain an exclusive sub-licensable license to exploit sequences against several additional targets, in which case Nona Biosciences shall be entitled to receive option exercise payments, potential milestone payments and tiered royalties if Moderna exercises such options.

Moderna is a global biotechnology company well recognized for its capabilities in the field of messenger RNA (“mRNA”) technology. The Agreement marks a significant milestone in the business development of Nona Biosciences and the Company, validating the potential of the Company’s technology platforms and innovation capabilities. The Company and Nona Biosciences are further exploring a broader application of their highly efficient, unique, and cutting-edge discovery platforms, empowering various research areas such as antibody, antibody-drug conjugates (ADC), T-cell therapy and NK cell therapy through multiple collaborations.

ABOUT NONA BIOSCIENCES

Nona Biosciences, a subsidiary wholly owned by the Company, is a global biotechnology company committed to providing I to ITM (Idea to IND) total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging the advantages of Harbour Mice[®] platforms and the experienced therapeutic antibody discovery team.

Harbour Mice[®] generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Integrating Harbour Mice[®] and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. The values of the antibody discovery platforms have been well validated by more than 50 industry and academic partners.

ABOUT HCAB

HCAb’s patented technology generates novel “heavy chain only” antibodies, which are about half the size of a typical IgG. These antibodies carry IgG-like PK properties and Fc-domain functions without the need for additional engineering or humanization. Lack of light chain also minimizes the issue of light chain mispairing and heterodimerization. These characteristics enable the development of products with attributes not achievable by conventional antibody platforms. In addition, HCAb derived multiple novel therapeutic antibody modalities, including single-domain antibodies, bi – and multi-specifics, antibody-drug conjugates, CAR-Ts, or VH domain-derived diagnostic or therapeutic products, are also achievable using this platform.

Warning under Rule 18A.05 of the Listing Rules: There is no assurance that any products under the Agreement will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Forward-Looking Statements

This announcement may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

The Company, the directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this announcement; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 11 November 2022

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive directors.